Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3

Bibliographic Details
Title: Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3
Authors: Martina Hinterleitner, Ruben Pfeiffer, Nils F. Trautwein, Bence Sipos, Stephan Singer, Silvio Nadalin, Alfred Königsrainer, Ulrich M. Lauer, Christian la Fougère, Lars Zender, Clemens Hinterleitner
Source: Frontiers in Endocrinology, Vol 14 (2024)
Publisher Information: Frontiers Media S.A., 2024.
Publication Year: 2024
Collection: LCC:Diseases of the endocrine glands. Clinical endocrinology
Subject Terms: neuroendocrine tumor, grading, G3, somatostatin receptor, PET, treatment, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
More Details: IntroductionNeuroendocrine neoplasms (NEN) are a rare and heterogenous group of tumors arising from neuroendocrine cells in multiple organs. Neuroendocrine tumors (NET) G3 encompass a small subgroup accounting for less than 10% of all neuroendocrine neoplasms. In contrast to NET G1 and G2 as well as neuroendocrine carcinomas (NEC), in NET G3 data on treatment and patient outcomes are still limited. Especially in a metastasized tumor stage, the role of surgery, peptide receptor radionucleotide therapy (PRRT), and systemic chemotherapy is not clearly defined.MethodsIn this real-life cohort, we consecutively analyzed clinical outcome in NET G3 patients receiving different diagnostic and treatment.Results and discussionWe found that even metastasized NET G3 patients undergoing surgery, or receiving radiation, somatostatin analogues (SSA), and PRRT showed a clear survival benefit. Interestingly, all treatment regimen were superior to classical chemotherapeutic agents. In addition, somatostatin receptor (SSTR) PET-CT, FDG PET-CT, and repetitive biopsies were shown to be useful diagnostic and prognostic tools in NET G3. Our study demonstrates that patients with highly proliferative NET G3 might benefit from less aggressive treatment modalities commonly used in low proliferative NEN.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-2392
Relation: https://www.frontiersin.org/articles/10.3389/fendo.2023.1285529/full; https://doaj.org/toc/1664-2392
DOI: 10.3389/fendo.2023.1285529
Access URL: https://doaj.org/article/f776dfeedfdc46f3b01b72156cb56fc2
Accession Number: edsdoj.f776dfeedfdc46f3b01b72156cb56fc2
Database: Directory of Open Access Journals
More Details
ISSN:16642392
DOI:10.3389/fendo.2023.1285529
Published in:Frontiers in Endocrinology
Language:English